

**MnVFC Announcement**

Date: April 24, 2023

To: MnVFC Providers

From: MnVFC Program

Re: **Expansion of vaccine administration routes**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

The Food and Drug Administration (FDA) approved the expansion of administration routes for Merck's MMR II, ProQuad, and varicella vaccines. They may now be given by either the subcutaneous (SC) or intramuscular (IM) route.

This expansion does not include the new MMR product, Priorix, which should be administered SC. Remind staff to be alert to which MMR product the clinic is using so that it is given by the indicated route.

Immunize.org has a handout that may be a helpful resource: [Administering Vaccines: Dose, Route, Site, and Needle Size \(https://www.immunize.org/catg.d/p3085.pdf\)](https://www.immunize.org/catg.d/p3085.pdf).

MnVFC Program  
651-201-5522 or 1-800-657-3970  
[www.health.state.mn.us/vfc](http://www.health.state.mn.us/vfc)